NasdaqHealth CarePharmaceutical PreparationsBURLINGTON, MA

Neuphoria Therapeutics Inc. NEUP

Ask your AI

Estimated market cap $13.80M5.41M shares, shares as of Sep 17, 2026CIK 1191070

Insider trades, 12 mo

—

No open-market trades

Congress trades, 24 mo

—

No disclosed trades

13F holders, Q2 2026

36.8% of shares · 6 added

13F holders

…

Lobbying, 12 mo

—

No lobbying filings

Federal contracts, 12 mo

—

None matched

Ask your AI:

Latest 10-Q

What changed in Neuphoria Therapeutics Inc.'s latest quarterly report, compared with the one before.

We have not read a recent 10-Q for this company yet.

Insider trades

Open-market trades from Form 4. 10b5-1 marks a plan set in advance.

No open-market insider trades reported since Oct 21, 2025. Insiders have two business days to file.

Recent insider trades
Insider	Traded	Type	Value	Since trade
Lynx1 Capital Management LP 10% owner	Oct 21, 2025 Form 4 ↗	Buy	+$3.3M 639,110 sh @ $5.14	-59.8%

All NEUP insider trades →Planned sales (Form 144): see notices

Insider trades

Open-market trades from Form 4. 10b5-1 marks a plan set in advance.

Loading…

13F holders

1.99M shares

22 funds report NEUP. Values checked against market prices.

Funds own 37% of shares (Q2 2026)

22 funds hold the stock.

Q3 2026: 11% · 5,560 of ~8,900 funds reported so far

Q2 20259.5%
Q3 20258.3%
Q4 202527%
Q1 202633%
Q2 202637%
Q3 2026 (so far)11%

Reports for the quarter ending Sep 30, 2026 are still coming in (10 positions so far, against 23 the quarter before), so we compare the two complete quarters before it.

Q2 2026. 5 new, 6 added to, 2 trimmed, 3 exited since Q1 2026.

Top 13F holders
#
1	Lynx1 Capital Management LP 13F ↗	875,328	$3.8M	unchanged
2	AdvisorShares Investments LLC 13F ↗	252,909	$1.1M	+62.8%
3	Vanguard Capital Management LLC 13F ↗	173,488	$758.1K	+76.1%
4	Shay Capital LLC 13F ↗	155,822	$680.9K	+3.2%
5	Balyasny Asset Management L.P. 13F ↗	142,228	$621.5K	unchanged
6	Citadel Advisors LLC 13F ↗	72,559	$317.1K	+275.4%
7	Geode Capital Management, LLC 13F ↗	49,516	$216.4K	-4.8%
8	Ikarian Capital, LLC 13F ↗	47,443	$207.3K	unchanged
9	Vanguard Fiduciary Trust Co 13F ↗	33,806	$147.7K	+0.6%
10	ADAR1 Capital Management, LLC 13F ↗	30,000	$131.1K	unchanged

Download CSV Every fund that holds NEUP, not only these ten. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

13F holders

Funds that report this stock, checked against market prices.

Loading…

Trades by members of Congress

Disclosed in dollar ranges, up to 45 days after the trade.

No recent congressional trades for this company.

Trades by members of Congress

Disclosed in dollar ranges, up to 45 days after the trade.

Loading…

Lobbying

What Neuphoria Therapeutics Inc. and its lobbying firms report each quarter.

No recent lobbying filings for this company.

Lobbying

What Neuphoria Therapeutics Inc. and its lobbying firms report each quarter.

Loading…

Institutional ownership over time

How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.

Funds holding the stock

Shares they report

Funds holding the stock by quarter

Q4 2024	8	—	79,720	$273.4K
Q1 2025	7	-1	163,114	$935.4K
Q2 2025	9	+2	177,963	$1.3M
Q3 2025	15	+6	195,338	$2.3M
Q4 2025	21	+6	1.47M	$5.7M
Q1 2026	19	-2	1.76M	$7.2M
Q2 2026	22	+3	1.99M	$8.7M
Q3 2026	10	-12	599,324	$2.1M

Each point is a quarter-end, from Q4 2024 to Q3 2026. A fund's 13F lists its long positions in US-listed securities as of the last day of the quarter and arrives up to 45 days later, so each point shows holdings at quarter-end, not on the day they were reported.

Common shares only; options and bonds are left out. When a fund amends a report, the amended version is the one counted.

The history follows the company's current CUSIP number (64136E102). If the company's shares were ever re-issued under a different CUSIP, the quarters before the change are not part of this series, so the first point (Q4 2024) can be later than the stock's first appearance in 13F reports.

Share counts are adjusted for stock splits; none took place between these quarters. Values are in dollars as reported at the time and are not adjusted.

A quarter appears once our daily update has built its summary. If a summary cannot be built, older reports are kept and the chart shows the quarters it has until the next update repairs it.

Institutional ownership over time

How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.

Loading…

More filings and data

Each opens the table.

Ownership stakes7 in 12 mo 8-K events1 in 90 days PatentsNone on record Short interestFINRA · updated Oct 15 Planned insider salesNone in 12 mo Executive payNone on record Wikipedia attentionNone on record SEC enforcementNone on record IPO history3 registrations Ownership stakes…8-K events…Patents…Short interest…Planned insider sales…Executive pay…Wikipedia attention…SEC enforcement…

About the company

The basics from the company’s SEC registration.

Legal name: Neuphoria Therapeutics Inc.
Address: 100 SUMMIT DR, BURLINGTON, MA 01803
Phone: 781-439-5551
Fiscal year ends: Jun 30
Filer category: Non-accelerated filer, smaller reporting company, emerging growth company
Incorporated in: Australia
Listed as: NEUP (Nasdaq)
Former names: BIONOMICS LIMITED/FI (until 2024)
SEC filings: All filings on SEC EDGAR ↗

About the company

The basics from the company’s SEC registration.

Loading…

$2.55−$0.03 (−1.16%) Nov 13 close

1M3M1Y

Oct 13, 2026Low $2.55 · High $3.48Nov 13, 2026

Aug 13, 2026Low $2.55 · High $3.98Nov 13, 2026

Nov 13, 2025Low $2.55 · High $5.48Nov 13, 2026

Congress purchase Congress sale Insider sale over $1M

Adjusted for stock splits; not for dividends. Where prices come from.

Live chart

Intraday and historical prices from TradingView. Quotes may be delayed.

Loading chart…

Information, not investment advice. Company matching is automatic; check the source before relying on one row.